SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MLTX is trending after a significant drop following mixed results from a Phase 3 trial, leading to concerns about the drug's efficacy compared to competitors. The community is debating whether the sell-off is an overreaction, with some speculating about a potential buyout and others focusing on the company's cash reserves and pipeline. Discussions also involve possible trading strategies, ranging from swing trades to long-term investments, amidst the volatility in the biotech sector.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals ($AUPH) is trending due to community speculation about a potential buyout offer, possibly around $12, amidst perceived unusual trading activity and a recent price drop. Some investors express frustration with the company's management and are hoping for a positive catalyst, while others point to long-term potential and recent insider buying as reasons for optimism in the broader sector.

Rezolve AI Plc operates in the mobile commerce industry with its cutting-edge engagement platform powered by artificial intelligence and machine learning. It develops AI-based mobile commerce and engagement solutions, simplifying the purchasing process by providing relevant information and facilitating seamless transactions with a single tap. The company enables retailers, brands, and manufacturers to create dynamic connections with consumers across mobile and desktop devices. Rezolve Ai was founded in 2016 and is headquartered in London, the United Kingdom.

Rezolve AI PLC .

Rezolve AI Limited

Rezolve AI ($RZLV) is trending amid accusations from a short seller, Fuzzy Panda Research, causing significant price volatility and debate among investors. The community is actively discussing the validity of the short report, the company's response, and the potential impact on upcoming earnings, with many expressing confidence in Rezolve's long-term prospects due to its partnerships and recent capital raise. Despite the controversy, some traders are seeing a buying opportunity, while others remain cautious, awaiting further developments.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

$WEEDCOIN.X is trending as a 'culture coin' for the cannabis community, sparking discussions about freedom, growth, and community. Some users are pointing to potential catalysts like cannabis legalization and touting it as better than traditional weed stocks. The community emphasizes that $WEEDCOIN.X is more than a token; it's a movement.

Bakkt Holdings, Inc. engages in the intersection of cryptoassets, loyalty and rewards, and payments. It also provides a platform to expand payment offerings, create new revenue streams, and increase customer loyalty. The company was founded in 2018 and is headquartered in Alpharetta, GA.

Bakkt Holdings Inc - Ordinary Shares - Class A

Bakkt Holdings Inc

BKKT is trending as the community discusses the appointment of Mike Alfred to the board and a new CEO, which some believe signals a strategic shift and potential for significant growth. Community members are speculating about upcoming news, a possible short squeeze, and the potential impact of the new leadership and focus on digital assets and AI. The company's recent debt payoff has also fueled speculation about a potential takeover.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending following news of a partnership with Google to enhance AI-powered shopping experiences. While some investors are excited about the potential growth, others express frustration with the stock's historical underperformance and question whether the partnership will provide an immediate catalyst. Community members are debating whether this is a turning point or another false start for the fintech giant.

Boqii Holding Ltd. operates as a holding company with interest in operating online pet stores. It provides services through its subsidiaries. The company was founded by Liang Hao, Tang Yingzhi, and Chen Di in December 2007 and is headquartered in Shanghai, China.

Boqii Holding Limited - Ordinary Shares - Class A

Boqii Holding Limited - ADR

Boqii Holding is trending due to significant volume and breakout signals, attracting attention as a China pet play. The community is discussing potential parabolic moves and Elliott Wave patterns, with some mentioning the possibility of a short squeeze. It is also on a list of stocks hitting new 52-week highs sorted by volume.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending as it hits new all-time highs, driven by strong financials, expansion into new products like prediction markets, and a favorable backdrop for fintech and crypto. Community members are actively discussing the sustainability of the rally, with some taking profits and others anticipating further growth toward targets like $150 or even $200. Discussions also include the potential impact of recent news, such as FINRA's potential easing of pattern day trading rules.

Carnival Corp. engages in the operation of cruise ships. It operates through the following business segments: North America and Australia (NAA) Cruise, Europe and Asia (EA) Cruise Operations, Cruise Support, and Tour and Others. The North America and Australia (NAA) Cruise segment includes the Carnival Cruise Line, Holland America Line, Princess Cruises, and Seabourn. The Europe and Asia (EA) Cruise Operations segment consists of AIDA, Costa, Cunard, and P&O Cruises (UK). The Cruise Support segment represents port destinations and private islands for the benefit of its cruise brands. The Tour and Other segment operates hotel and transportation operations of Holland America Princess Alaska Tours. The company was founded in 1972 and is headquartered in Miami, FL.

Carnival Corp. - Ordinary Shares (Paired Stock)

Carnival Corp

CCL is trending as investors react to recent earnings, with mixed sentiment regarding the stock's future performance. While the company beat expectations and raised guidance, the stock price experienced a sell-off, sparking debate about potential overvaluation and profit-taking. Some traders are anticipating a continued climb, while others are hedging their positions or expecting further declines.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA is trending downwards, with community sentiment reflecting concern and frustration as the stock tests new lows. Investors are actively debating whether the dip presents a buying opportunity or signals deeper issues with the company's growth and valuation, especially when compared to sector peers. Some are optimistic about long-term potential driven by expansion and menu innovation, while others express doubts about the current economic climate impacting consumer spending at fast-casual restaurants.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Gilead Sciences Surges 26.5% YTD: Buy, Sell or Hold the Stock?

Gilead surges 26.5% YTD in 2025 as HIV franchise gains momentum with Yeztugo approval, offsetting cell therapy pressures.

IONS' Rare Neurological Disease Drug Meets Late-Stage Study Goal

Ionis' zilganersen hits its phase III goal in Alexander disease, paving the way for a potential FDA filing in early 2026.

Why GSK (GSK) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

U.S. President Donald Trump on Monday linked autism to both childhood vaccines and the use of Tylenol by pregnant women and children, claims that decades of scientific research have not supported.&nbsp;Meanwhile, Kenvue, the maker of Tylenol, rejected the claims. “We believe independent, sound science clearly shows that taking acetaminophen does not cause autism. We strongly disagree with any suggestion otherwise and are deeply concerned with the health risk this poses for expecting mothers,” according to a Reuters&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/trump-expected-link-autism-with-tylenol-experts-say-more-research-needed-2025-09-22/">report</a>, citing a company statement.&nbsp;Kenvue, which was spun off from Johnson &amp; Johnson in 2023, saw its shares fall 7.5% during Monday’s session to a record low before recovering 4.4% in extended trading.In a White House news conference, Trump repeatedly advised women and parents not to use the painkiller, saying, “Don’t take Tylenol. Fight like hell not to take it,” while acknowledging he was not a doctor.Standing alongside Health Secretary Robert F. Kennedy Jr., a longtime vaccine critic, Trump also called for a reexamination of vaccine schedules, urging separate measles, mumps, and rubella shots, and stating that the hepatitis B vaccine should not be administered until age 12, despite longstanding medical guidance recommending it within 24 hours of birth.&nbsp;Tylenol is Kenvue's largest brand, accounting for a mid-to-high single-digit percentage of total sales, The Wall Street Journal&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/health/healthcare/trump-autism-report-announcement-eb7c90c8?mod=hp_lead_pos1">noted</a>, citing Morningstar. Trump’s warning also comes as Kenvue continues to face litigation over acetaminophen, with hundreds of lawsuits alleging a link to autism or ADHD currently under appeal after a federal judge last year ruled the scientific evidence unreliable.Meanwhile, acetaminophen remains an important option for pregnant women, and vaccines have saved millions of lives, with UNICEF estimating at least 154 million lives preserved over the last 50 years.The Trump administration also announced steps to position leucovorin, a form of folic acid currently used in chemotherapy support, as a treatment for autism-related symptoms.&nbsp;The FDA approved a version of the drug from GSK and cited a review of 40 patients with cerebral folate deficiency, a rare metabolic disorder linked to neurological symptoms. Medicaid coverage for leucovorin will be extended to autism patients, with expectations that private insurers will follow.Researchers reiterated that there is no solid evidence that acetaminophen causes autism. A 2024 study using 2.5 million Swedish children found no causal relationship. In 2025, a review of 46 previous studies was done, which found an association, but it does not show cause and effect.&nbsp;Researchers advised that pregnant women who need acetaminophen should continue taking it at the lowest dose and for the shortest time. Bigger, randomized trials are still needed to determine leucovorin's potential.On Stocktwits, retail sentiment for Kenvue was ‘extremely bullish’ amid ‘extremely high’ message volume.One bullish user said the administration’s comments unfairly singled out Kenvue as if Tylenol were the only acetaminophen brand on the market, adding that people weren’t about to stop using the drug for everyday needs and calling the concerns overblown.<stembedurl>https://stocktwits.com/FatherofTrades/message/629593979</stembedurl>Another user said that they were buying every dip in Kenvue shares and planned to hold through the lawsuits and any eventual settlement.<stembedurl>https://stocktwits.com/StockCapture/message/629592908</stembedurl><a href="https://stocktwits.com/symbol/KVUE">Kenvue’s stock</a> has declined 18.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Kenvue logo is seen displayed on a smartphone screen. U.S. health officials will hold a press conference on autism, which is expected to link Kenvue's Tylenol to the disease. (Illustration by Thomas Fuller/Getty Images)

Kenvue Stock Hits Record Low As Trump Urges Pregnant Women To ‘Fight Like Hell’ Against Tylenol: Retail Stays Bullish

Investors weighed political scrutiny and unproven health claims as Tylenol’s maker faced renewed controversy, sparking volatility in Kenvue’s stock.

Equity

Here's Why GSK (GSK) is a Strong Growth Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

RHHBY to Acquire 89bio for $3.5B, Add Late-Stage MASH Drug to Pipeline 

Roche is set to acquire 89bio for $3.5B, adding late-stage MASH drug pegozafermin to its cardiovascular, renal, and metabolic pipeline. 

GSK to Invest $30B in U.S. R&D and Manufacturing Over 5 Years

GSK commits $30B to U.S. R&D and manufacturing, with advanced AI-driven biopharma facilities set to expand jobs and innovation.

LLY's $5B Virginia Plant Plan: Will U.S. Manufacturing Shift Pay Off?

Eli Lilly will invest $5B in a new Virginia plant to make cancer drugs, creating 650 jobs amid Trump's tariff push.

U.S. stocks appear set for a cautious opening on Wednesday as the Federal Reserve gets ready to announce its latest interest rate decision.Data from the CME FedWatch&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a> indicates a 94% probability of a 25-basis-point rate cut announcement on Wednesday.While Dow Jones futures were up 0.03% at the time of writing, the S&amp;P 500 futures fell 0.07%, while the tech-heavy Nasdaq 100’s futures declined 0.1%. Futures of the Russell 2000 index were up 0.02%.Meanwhile, the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY) was down 0.07% at the time of writing, while&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust</a> (QQQ) fell 0.08% on Wednesday morning. Retail sentiment around the S&amp;P 500 ETF on Stocktwits was in the ‘bullish’ territory.Asian markets ended Tuesday’s trading session on a largely negative note, with the KOSPI declining the most at 1.06%, followed by the TWSE Capitalization Weighted Stock index at 0.75%, and the Nikkei 225 index at 0.17%.The Hang Seng index surged 1.86%, while the Shanghai Composite gained 0.37%.Stocks To Watch<ul><li>Workday Inc. (WDAY): Workday shares surged 8% in Wednesday’s pre-market session after Elliott Investment Management announced a $2 billion investment in the company.</li><li>Microsoft Corp. (MSFT), Nvidia Corp. (NVDA), Alphabet Inc. (GOOG) (GOOGL): U.S. tech giants announced a $40 billion investment in the U.K. amid President Donald Trump’s visit to the nation.</li><li>StubHub Holdings Inc. (STUB): The ticket reseller raised nearly $800 million in its initial public offering (IPO). The stock is set to debut on Wednesday.</li><li>GSK Plc. (GSK), Eli Lilly and Co. (LLY): The two pharmaceutical giants announced plans to build new plants in the U.S. to mitigate the impact of tariffs partly.</li></ul>&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/martin-shkreli-shorts-opendoor-stock/chwyrOyRdz6">‘Pharma Bro’ Martin Shkreli Shorts Opendoor Technologies, Stock Tumbles 5%</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

People walk by the New York Stock Exchange

Dow Futures Stall Ahead Of Fed’s Interest Rate Decision Today: WDAY, MSFT, GOOGL, NVDA Among Stocks To Watch

While Dow Jones futures were up 0.03% at the time of writing, the S&P 500 futures fell 0.07%.

GSK’s U.S.-listed shares ticked&nbsp;nearly 2% higher after-hours Tuesday after the British drugmaker said it will pour $30 billion into U.S. research and manufacturing over the next five years,&nbsp;the latest move by a major pharmaceutical company to expand domestic production under President Donald Trump’s "America first" push.The investment includes a fresh $1.2 billion package to build new labs and factories, expand drug-substance production, and roll out AI and digital technology across five existing plants. GSK said the money will support hundreds of new high-skilled jobs alongside construction work.A centerpiece of the plan is a new biologics “flex” factory at Upper Merion, Pennsylvania, scheduled to break ground in 2026. The site will focus on medicines for respiratory illnesses such as asthma and COPD, as well as cancer. GSK is also adding new auto-injector and assembly capabilities as part of the push.“This week’s State Visit brings together two countries that have led the world in science and healthcare innovation,” CEO Emma Walmsley said, adding that the company’s $30 billion commitment would further cement its U.S. research and supply-chain base.The move comes as other global drugmakers step up U.S. spending. Earlier Tuesday, Eli Lilly announced a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-to-set-up-5-billion-facility-in-virginia/chwymFcRdzj">$5 billion facility west of Richmond, Virginia,</a> that will make complex cancer and autoimmune medicines and create more than 2,400 jobs. Johnson &amp; Johnson and AstraZeneca have each pledged around $50 billion in U.S. expansion by 2030.Big Pharma’s building spree&nbsp;indicates both opportunity and pressure&nbsp;as&nbsp;several companies are still trying to patch supply-chain weaknesses exposed during the Covid-19 pandemic, while the Trump administration has threatened tariffs of up to 250% on imported medicines.&nbsp;GSK, which employs about 15,000 people in the U.S., has already broken ground on an $800 million facility in Marietta, Pennsylvania, that will double that site’s capacity. Last year, GSK got 1.7 billion packs of medicine and 400 million vaccine doses into the hands of patients. By 2030, it wants to reach 2.5 billion people worldwide.On Stocktwits, retail sentiment for GSK was ‘neutral’ amid ‘normal’ message volume.<a href="https://stocktwits.com/symbol/GSK">GSK’s U.S.-listed stock</a> has risen 22.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of GSK plc is displayed on a smartphone screen, on April 26, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

GSK Stock Climbs After-Hours On $30B US Investment Pledge As Trump Pressures Big Pharma To Build In America

The plan includes $1.2 billion for a new biologics factory in Upper Merion, Pennsylvania, along with AI upgrades and expanded drug production across existing U.S. sites.

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

GSK
Glaxosmithkline plc - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest GSK News

GSK Glaxosmithkline plc - ADR